Prevalence and Trends of Post-COVID-19 Sequelae Among U.S. Adults With Prior COVID-19 Infection, 2022-2024.
- 1Infectious Disease, Henry Ford St. John Hospital, Detroit, USA.
- 2Biostatistics, Henry Ford St. John Hospital, Detroit, USA.
Abstract
Background
Post-acute sequelae of SARS-CoV-2 infection (PASC) affect a substantial proportion of U.S. adults, involving multiple organ systems and resulting in significant disability and diminished quality of life. Population-level PASC estimates include individuals without prior COVID-19 infection and therefore do not accurately reflect postinfection risk required for effective risk stratification. We estimated the prevalence and trends of PASC among U.S. adults with prior COVID-19.Methods
We analyzed data from the National Health Interview Survey (2022-2024), a nationally representative survey of the U.S. civilian noninstitutionalized population. Adults reporting prior COVID-19 infection were asked whether they ever experienced symptoms lasting ≥3 months that were not present before infection; those answering yes were classified as having PASC. Weighted analyses accounted for the complex survey design.Results
Among 42,872 adults with prior COVID-19, 6,822 reported symptoms lasting three months or longer, indicating PASC. Prevalence declined from 19.7% in 2022 to 15.1% in 2023 and 13.7% in 2024 (P<0.001 for 2022 vs subsequent years). Despite this decline, more than 21 million U.S. adults reported having experienced PASC in 2023 and 2024. Prevalence was higher among women and adults aged 35-64 years than among men and younger or elderly individuals. A lower prevalence was observed among Asian adults, whereas a higher prevalence was noted among American Indian, Alaska Native, and multiracial adults.Conclusions
Despite declining prevalence, PASC remains common among U.S. adults with prior COVID-19. These nationally representative postinfection estimates provide clinically relevant risk information to guide patient counseling, health system planning, and ongoing surveillance.
Related
- Acceptability, Feasibility, and Preliminary Efficacy of a Digital Cognitive Intervention for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in Older Adults
- International trends in clozapine utilisation prevalence in adults, adolescents and older people: An observational study in 42 countries between 2015 and 2024
- Multi-omic analysis of post-acute sequelae of COVID-19 (PASC)
- Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity
- Prevalence and Functional Outcomes of Post-Exertional Malaise among Adults with prior COVID-19: Results from a Representative Survey of New York City Residents
BibTeX
@article{bhargava2026prevalence,
title = {{Prevalence and Trends of Post-COVID-19 Sequelae Among U.S. Adults With Prior COVID-19 Infection, 2022-2024.}},
author = {Ashish Bhargava and Susan Szpunar},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116792},
url = {https://europepmc.org/article/MED/42921630},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prevalence and Trends of Post-COVID-19 Sequelae Among U.S. Adults With Prior COVID-19 Infection, 2022-2024.
AU - Ashish Bhargava
AU - Susan Szpunar
PY - 2026
DA - 2026/09/23
JO - Cureus
DO - 10.7759/cureus.116792
UR - https://europepmc.org/article/MED/42921630
AB - Background Post-acute sequelae of SARS-CoV-2 infection (PASC) affect a substantial proportion of U.S. adults, involving multiple organ systems and resulting in significant disability and diminished quality of life. Population-level PASC estimates include individuals without prior COVID-19 infection and therefore do not accurately reflect postinfection risk required for effective risk stratification. We estimated the prevalence and trends of PASC among U.S. adults with prior COVID-19.Methods We analyzed data from the National Health Interview Survey (2022-2024), a nationally representative survey of the U.S. civilian noninstitutionalized population. Adults reporting prior COVID-19 infection were asked whether they ever experienced symptoms lasting ≥3 months that were not present before infection; those answering yes were classified as having PASC. Weighted analyses accounted for the complex survey design.Results Among 42,872 adults with prior COVID-19, 6,822 reported symptoms lasting three months or longer, indicating PASC. Prevalence declined from 19.7% in 2022 to 15.1% in 2023 and 13.7% in 2024 (P<0.001 for 2022 vs subsequent years). Despite this decline, more than 21 million U.S. adults reported having experienced PASC in 2023 and 2024. Prevalence was higher among women and adults aged 35-64 years than among men and younger or elderly individuals. A lower prevalence was observed among Asian adults, whereas a higher prevalence was noted among American Indian, Alaska Native, and multiracial adults.Conclusions Despite declining prevalence, PASC remains common among U.S. adults with prior COVID-19. These nationally representative postinfection estimates provide clinically relevant risk information to guide patient counseling, health system planning, and ongoing surveillance.
SN - 2168-8184
ER -